Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 12Carcinoma, Renal Cell 11Lymphoma 3Neoplasms 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Colorectal Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Polycythemia Vera 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Multiple Myeloma 1Margins of Excision 1Kidney Neoplasms 1Hodgkin Disease 1Hematologic Neoplasms 1HTLV-I Infections 1Carcinoma 1Breast Neoplasms 1Breast Carcinoma In Situ 1Adenocarcinoma 1

Interventions

Carboplatin 23Cisplatin 19pembrolizumab 14Paclitaxel 12Gemcitabine 12Pemetrexed 11130-nm albumin-bound paclitaxel 9Everolimus 8Cetuximab 8Fluorouracil 7Axitinib 6osimertinib 5durvalumab 5Sunitinib 5Radiotherapy 5Erlotinib Hydrochloride 5Docetaxel 5Cyclophosphamide 5Albumin-Bound Paclitaxel 5Sorafenib 4Radiation 4Nivolumab 4Ipilimumab 4vosaroxin 3Radiotherapy, Intensity-Modulated 3Octreotide 3Irinotecan 3Bevacizumab 31-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 3pralsetinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma × Interferon alpha-2 × Clear all
NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡